Choosing Second-Line Therapy for Patients With Urothelial Carcinoma

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Three additional clinical trials will study nadofaragene firadenovec-vncg for the treatment of patients with non-muscle invasive bladder cancer.

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.